Your session is about to expire
← Back to Search
VX-970 + Topotecan for Small Cell Cancers
Study Summary
This trial is studying the side effects and best dose of VX-970 (M6620) when given with topotecan and to see how well it works in treating small cell lung cancer.
- Extrapulmonary Small Cell Carcinoma
- Neuroendocrine Carcinoma
- Non-Small Cell Lung Cancer
- Small Cell Lung Cancer
- Cervical Cancer
- Ovarian Tumors
Eligibility Criteria
Inclusion Criteria
You will be eligible if you check “Yes” for the criteria belowTimeline
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Side effects data
From 2020 Phase 3 trial • 444 Patients • NCT03061812Awards & Highlights
Trial Design
Find a Location
Who is running the clinical trial?
Media Library
- You have a type of tumor that can potentially be cured with treatment.You are currently taking any other experimental medications.You have had allergic reactions to similar drugs or substances used in the study.You have received chemotherapy treatment in the past.If you have certain genetic mutations in your lung cancer, you should have already received specific medications approved by the FDA, as well as chemotherapy.
- Group 1: 1/Phase I VX-970 (M6620) + topotecan
- Group 2: 2/Phase II VX-970 (M6620) + topotecan
- No Placebo-Only Group - All patients enrolled in this study will receive some form of active treatment.
- Screening: It may take up to 3 Weeks to process to see if you qualify in this trial.
- Treatment: The duration you will receive the treatment varies.
- Follow Ups: You may be asked to continue sharing information regarding the trial for 6 Months after you stop receiving the treatment.
Frequently Asked Questions
What is the past research on Topotecan's effectiveness?
"As of right now, there are 74 clinical trials underway that are studying Topotecan. Out of these, 17 are in Phase 3. Most of the research being conducted for Topotecan is happening in Scottsdale, Arizona; however, there are 3407 locations worldwide where studies involving Topotecan are taking place."
How many participants are in this clinical trial?
"This particular clinical trial is no longer looking for new participants. The study was originally posted on July 30th, 2015 and the most recent update was on March 17th, 2022. With that said, there are currently 6963 different trials involving patients with uterine cervical neoplasms and 74 trials testing Topotecan that actively recruiting patients."
What are the main conditions that Topotecan is used to treat?
"Topotecan is a medication that oncologists often prescribe to patients with ovarian cancer. Additionally, this drug can be used to treat leukemia, myelocytic sarcoma, and other malignant neoplasms."
Are there any patients still needed for this clinical trial?
"Currently, this clinical trial is not accepting any new patients. Although, it's worth noting that this study was originally posted on 7/30/2015 and was last edited on 3/17/2022. If you're interested in other studies, 6963 different trials for uterine cervical neoplasms are actively recruiting participants and 74 trials involving Topotecan are searching for patients."
Share this study with friends
Copy Link
Messenger